Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

In January, the Food and Drug Administration approved a new pain medicine called Journavx (suzetrigine), made by Vertex Pharmaceuticals. It’s the first time in 25 years the agency has given the green ...

But now the FDA has approved the first painkiller, Journavx, which works in a completely different way: not on the brain and spinal cord but on the nerves throughout the rest of the body.

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to severe acute pain in more than 20 years.

JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. This press release features multimedia.

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

It's the first new type of painkiller in 20 years. And it's just a few weeks away from being here in local pharmacies. Canada victory over USA most-watched NHL game ever as ESPN, Sportsnet smash ...